Has Brittany Lenz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $429,584 in general payments to Brittany Lenz, MD across 1,178 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brittany Lenz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brittany Lenz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brittany Lenz, MD

Dermatology · Jbsa-Lackland, TXNPI 1538433305

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $354,268 of the $429,584 with a category attached, or 82.5%. 34 manufacturers reported payments, led by Johnson & Johnson at 53.6% of the total. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$429,584in general payments, 2019–2025

Across 1,178 payments — averaging $364.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$230K
Dermavant Sciences, Inc.$58K
Janssen Scientific Affairs, LLC$39K
Lilly USA, LLC$39K
Galderma Laboratories, L.p.$34K
Organon$14K
plus $15K from 28 others

What the payments were for

Consulting fees$12,3393%
Speaking & faculty fees$354,26882%
Travel & lodging$38,2429%
Food & beverage$24,0326%
Education$7030%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	298	$230,228
Dermavant Sciences, Inc.	102	$58,127
Janssen Scientific Affairs, LLC	37	$39,247
Lilly USA, LLC	95	$38,915
Galderma Laboratories, L.p.	117	$33,654
Organon	33	$14,497
UCB, Inc.	43	$5,748
AbbVie	92	$1,481
E.r. Squibb & Sons, L.L.C.	62	$1,263
Regeneron Healthcare Solutions, Inc.	43	$964
Incyte Corporation	51	$934
Sun Pharmaceutical Industries Inc.	28	$735
Sanofi	24	$520
Arcutis Biotherapeutics, Inc.	29	$376
Novartis	18	$338
Pfizer	22	$317
Ortho Dermatologics, A Division Of Bausch Health US, LLC	18	$311
Almirall LLC	8	$296
Amgen	15	$276
LEO Pharma Inc.	9	$195
Genentech USA, Inc.	1	$125
DUSA Pharmaceuticals, Inc.	1	$123
Journey Medical Corporation	5	$123
Boston Scientific	3	$114
Mayne Pharma Commercial LLC	4	$102
Sanofi-aventis U.S. LLC	1	$100
Revance Therapeutics, Inc.	3	$90
Biofrontera Inc.	5	$88
Bristol Myers Squibb	1	$73
VYNE Pharmaceuticals Inc.	2	$72
Botanix SB Inc	4	$69
Boehringer Ingelheim	2	$33
EPI Health, LLC	1	$29
LNHC, Inc	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$265,283
VTAMA$70,404
OLUMIANT$36,100
NEMLUVIO$16,350
SIMPONI ARIA$11,692
STELARA$4,771
Bimzelx$3,606
Erivedge$125
Seysara$125
LEVULAN KERASTICK$123
BLU-U$123
Sotyktu$123
DUPIXENT$112

How this compares

$429,584 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024

$225,411

Medicare patients

450

Services billed

5,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	19	$89,557
Clobetasol Propionate	38	$1,892
Doxycycline Hyclate	25	$847
Ketoconazole	66	$738
Triamcinolone Acetonide	32	$348
Spironolactone	18	$184
Famciclovir	11	$13

Paid to pharmacies, not to this prescriber.

Other dermatology in Jbsa-Lackland

Edward LainAustin$2.5M
William CragunSan Antonio$2.2M
Alpesh DesaiHouston$1.6M
Craig TellerBellaire$1.3M
Jennifer CatherDallas$1.3M
Emily BeckerSan Antonio$1.2M
Ross RaduskyDallas$1.2M
Joseph MerolaDallas$1.2M
Daniel CarrascoAustin$1.1M
Dale SchaeferAustin$1M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →